Huzhou Nanxun Xingxiang Building Materials Co., Ltd. – Trademark Portfolio
Entity Type: 99
Huzhou Nanxun Xingxiang Building Materials Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include QSVIFX. The owner is based in Nanxun Dist., Huzhou.
Plaza, No. 888 Nanxun Ave., Dongqian St.
No.1603, Bldg. 2, Nanxun Jiayuan Central
Nanxun Dist., Huzhou 310000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Huzhou Nanxun Xingxiang Building Materials Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Huzhou Nanxun Xingxiang Building Materials Co., Ltd. have?
Huzhou Nanxun Xingxiang Building Materials Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Huzhou Nanxun Xingxiang Building Materials Co., Ltd. file in?
Huzhou Nanxun Xingxiang Building Materials Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Huzhou Nanxun Xingxiang Building Materials Co., Ltd.'s most well-known trademarks?
Huzhou Nanxun Xingxiang Building Materials Co., Ltd.'s registered trademark portfolio includes well-known marks such as QSVIFX. These are among 1 currently registered trademark in the portfolio.
What is Huzhou Nanxun Xingxiang Building Materials Co., Ltd.'s trademark registration success rate?
Huzhou Nanxun Xingxiang Building Materials Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.